Table 2.
Summary of adverse events
| Placebo (n = 4) | Tirzepatide 2.5–10.0 mg (n = 10) | Tirzepatide 2.5–15.0 mg (n = 10) | |
|---|---|---|---|
| Any TEAE | 4 (100) | 10 (100) | 10 (100) |
| Mild | 4 (100) | 10 (100) | 10 (100) |
| Moderate | 1 (25) | 3 (30) | 0 |
| Treatment-related AEs | 0 | 9 (90) | 10 (100) |
| Any SAE | 1 (25) | 0 | 0 |
| Discontinuation due to AEs | 1 (25) | 0 | 0 |
| TEAEs by preferred terma | |||
| Decreased appetite | 0 | 5 (50) | 8 (80) |
| Diarrhea | 0 | 6 (60) | 4 (40) |
| Hyperlipidemia | 3 (75) | 5 (50) | 2 (20) |
| Abdominal distension | 0 | 2 (20) | 5 (50) |
| Nausea | 0 | 1 (10) | 4 (40) |
| Lipase increased | 0 | 1 (10) | 3 (30) |
| Hiccups | 0 | 1 (10) | 1 (10) |
| Fatigue | 0 | 2 (20) | 0 |
| Flatulence | 0 | 1 (10) | 1 (10) |
| Hypoglycemia | 0 | 1 (10) | 1 (10) |
| Hypokalemia | 1 (25) | 1 (10) | 0 |
| Injection-site reaction | 0 | 0 | 2 (20) |
| Nasopharyngitis | 0 | 0 | 2 (20) |
| URTI | 2 (50) | 0 | 0 |
| Urinary tract infection | 0 | 2 (20) | 0 |
Data are presented as number of patients (%)
aListings include any TEAE reported in ≥ 2 patients
AE adverse event, SAE serious adverse event, TEAE treatment-emergent adverse event, URTI upper respiratory tract infection